Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Zadar

18 clinical trials in Zadar, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Zadar at a glance
18
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

18 trials in Zadar

Open in trial search
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Morf-057
  • Sponsor:Morphic Therapeutic Inc.
Countries:CroatiaCroatia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab
  • Sponsor:Anaptysbio Inc.
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Zadar

What the registry says about research in the country

01 Autoimmune Conditions

Innovative research focusing on psoriatic arthritis, systemic sclerosis, and systemic lupus erythematosus. Clinical trials are evaluating new therapeutic approaches including zasocitinib and efgartigimod for improving patient outcomes.

  • Psoriatic Arthritis Treatment
  • Systemic Sclerosis Management
  • Lupus Therapy Development

Studies aim to address both skin manifestations and systemic symptoms of these conditions.

02 Neurological Disorders

Groundbreaking research in multiple sclerosis treatment, testing new therapeutic agents like remibrutinib compared to established treatments. Focus on reducing relapse frequency and improving patient quality of life.

  • MS Relapse Prevention
  • Novel Treatment Comparisons
  • Disease Progression Management

Emphasis on developing more effective treatment options with better tolerability profiles.

03 Gastrointestinal Diseases

Comprehensive studies on Crohn's disease, ulcerative colitis, and celiac disease. Trials evaluating innovative treatments including MORF-057, rosnilimab, and ZED1227 for improving disease management.

  • Inflammatory Bowel Disease Therapy
  • Celiac Disease Management
  • Endoscopic Response Assessment

Research focuses on both symptom control and mucosal healing.

04 Respiratory Conditions

Advanced research in severe eosinophilic asthma and COPD. Studies evaluating dexpramipexole and CHF6001 DPI as potential treatments for improving respiratory function and reducing exacerbations.

  • Asthma Exacerbation Prevention
  • COPD Management
  • Triple Therapy Enhancement

Focus on developing targeted therapies for severe respiratory conditions.

05 Cardiovascular Research

Important studies in atrial fibrillation and hypertriglyceridemia. Clinical trials examining new anticoagulants like milvexian and treatments for metabolic disorders.

  • Stroke Prevention
  • Lipid Management
  • Cardiovascular Risk Reduction

Research aims to improve cardiovascular outcomes and prevent complications.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).